Skip to main content

Advertisement

Table 1 Levels of YKL-40 and clinical characteristics of patients with ESCC

From: Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma

Characteristics Case numbers YKL-40(ng/ml)
Median(range) p Valuea
Age, years
<60 81 71.56(6.95-340.70) 0.001
≥60 69 122.36(21.32-502.05) 0.001
Gender
Male 113 93.12(11.56-430.83) 0.784
Female 37 111.60(6.95-502.05) 0.784
pT status
pT1 5 93.12(21.32-264.66) 0.975
pT2 21 104.27(30.26-430.83) 0.975
pT3 65 91.55(6.95-421.34) 0.975
pT4 45 101.50(14.64-351.66) 0.975
pN status
pN0 57 97.27(6.95-430.83) 0.617
pN1 77 97.03(13.32-421.34) 0.617
pM status
pM0 107 93.24(6.95-430.83) 0.198
pM1 32 108.82(14.64-419.22) 0.198
pTNM status
Stage I 7 93.12(42.26-264.66) 0.604
Stage II 40 97.27(6.95-430.83) 0.604
Stage III 58 92.40(13.32-421.34) 0.604
Stage IV 32 108.82(14.64-419.22) 0.604
Tumor grade
Grade 1 24 108.39(24.95-234.89) 0.579
Grade 2 57 94.21(11.56-376.09) 0.579
Grade 3 41 71.02(6.95-419.22) 0.579
  1. aKruskal-Wallis test.